 | | | | The United States had administered 434,486,889 doses of COVID-19 vaccines in the country as of Wednesday morning and distributed 541,361,525 doses, the U.S. Centers for Disease Control and Prevention said. | | | | | | China's CanSino Biologics Inc has applied for emergency use authorization in Brazil for its COVID-19 vaccine, Brazil's health regulator Anvisa said on Wednesday. | | | | | | U.S. National Institutes of Health scientists played "a major role" in developing Moderna Inc's COVID-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH Director Dr. Francis Collins told Reuters on Wednesday. | | | | | | A U.S. judge gave Johnson & Johnson a temporary reprieve from tens of thousands of claims that its talc-based products cause cancer, but handed the drugmaker a potential setback by moving the cases to a court where the outcomes might be less favorable. | | | | | | France is at the beginning of a fifth wave of the coronavirus epidemic, Health Minister Olivier Veran said on Wednesday. | | | | | | Israel's pandemic advisory board on Wednesday backed administering Pfizer's and BioNTech's COVID-19 vaccine to children age 5-11, health officials said, as a fourth wave of infections subsides nationwide. | | | | | | The risk of measles outbreaks is high after more than 22 million infants missed their first vaccine doses during the COVID-19 pandemic in 2020, the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) warned. | | | | | | The Americas is facing an impending crisis in routine vaccinations because of the coronavirus pandemic, the Pan American Health Organization (PAHO) said on Wednesday, and vaccinations against COVID are behind where they should be. | | | | | | The U.S. Food and Drug Administration classified the recall of Ellume's over-the-counter COVID-19 home test as Class 1, the most serious type of recall, after the Australian diagnostic test maker removed some of its tests from the market last month. | | | | | | Roche Holding AG , still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc's Aduhelm, saying that its medication would be priced competitively. | | | | | |
